Trials / Completed
CompletedNCT06165237
A Study to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2"
A Phase I Clinical Trial to Evaluate the Drug-drug Interaction and Safety Between "BR6001-1" and "BR6001-2" in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this clinical trial is to evaluate the drug-drug interaction and safety between "BR6001-1" and "BR6001-2" in healthy adult volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BR6001-1 | One tablet administered alone, Once a day |
| DRUG | BR6001-2 | One tablet administered alone, Once a day |
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2023-05-09
- Completion
- 2023-05-09
- First posted
- 2023-12-11
- Last updated
- 2024-02-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06165237. Inclusion in this directory is not an endorsement.